Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Research

Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study

Authors: David Danese, Diana Goss, Carla Romano, Catherine Gupta

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

Without effective intervention, primary hyperoxaluria type 1 (PH1) causes oxalate-induced kidney damage, leading to end-stage kidney disease and serious complications throughout the body. Although PH1 carries a heavy burden that impacts quality of life, literature on the experiences of those living with PH1 and caring for patients with PH1 is limited. This study aimed to describe the diagnostic journey in PH1 and characterize patients’ and caregivers’ self-reported experiences throughout the disease course.

Methods

This was an observational study involving in-depth, semi-structured telephone interviews. Dominant trends were assessed using constant comparative analysis to identify themes in interviewees’ descriptions of their experiences. Individuals aged ≥ 12 years and caregivers of children aged 6–17 years with genetically confirmed PH1 were eligible. Informed consent/assent and ability to read and speak English were required.

Results

Interviewees (16 patients, 12 caregivers) reported a prolonged diagnostic journey due to low disease awareness, among other factors. Upon diagnosis, PH1 was frequently symptomatic, typically involving kidney stone-related symptoms but also potentially symptoms arising beyond the kidneys. PH1 most commonly led to worry and social impairment in adolescents, impaired physical function in adults, and a range of impacts on caregivers. In late-stage disease, dialysis was the most burdensome aspect of living with PH1 (due to time requirements, limitations from living with a catheter, etc.), and this burden was exacerbated by the COVID-19 pandemic. Benefits desired from PH1 management included reductions in laboratory measures of oxalate burden, kidney stone and urination frequency, and oxalate-related skin ulcers.

Conclusions

PH1 greatly impacts patients’ and caregivers’ lives, primarily due to burdensome disease manifestations and associated emotional, physical, and practical impacts, as well as disease management challenges – particularly those related to dialysis in late-stage disease.
Literature
3.
go back to reference Shee K, Stoller ML. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol. 2022;19(3):137–46.CrossRefPubMed Shee K, Stoller ML. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol. 2022;19(3):137–46.CrossRefPubMed
4.
go back to reference Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. 2020;15(7):1056–65.CrossRefPubMedPubMedCentral Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol. 2020;15(7):1056–65.CrossRefPubMedPubMedCentral
5.
go back to reference Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927–49.CrossRefPubMed Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927–49.CrossRefPubMed
6.
go back to reference Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729–36.CrossRefPubMed Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729–36.CrossRefPubMed
7.
go back to reference van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3855–62.CrossRefPubMed van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3855–62.CrossRefPubMed
8.
go back to reference Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, et al. Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study. Front Med (Lausanne). 2021;8: 703305.CrossRefPubMed Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, et al. Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study. Front Med (Lausanne). 2021;8: 703305.CrossRefPubMed
9.
go back to reference Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559–70.CrossRefPubMedPubMedCentral Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol. 2015;26(10):2559–70.CrossRefPubMedPubMedCentral
10.
go back to reference Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77(5):443–9.CrossRefPubMed Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int. 2010;77(5):443–9.CrossRefPubMed
11.
go back to reference Soliman NA, Nabhan MM, Abdelrahman SM, Abdelaziz H, Helmy R, Ghanim K, et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol Ther. 2017;13(3):176–82.CrossRefPubMedPubMedCentral Soliman NA, Nabhan MM, Abdelrahman SM, Abdelaziz H, Helmy R, Ghanim K, et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol Ther. 2017;13(3):176–82.CrossRefPubMedPubMedCentral
12.
go back to reference Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol. 2013;28(12):2273–81.CrossRefPubMed Cochat P, Groothoff J. Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol. 2013;28(12):2273–81.CrossRefPubMed
13.
go back to reference Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86(6):1197–204.CrossRefPubMed Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86(6):1197–204.CrossRefPubMed
14.
go back to reference Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–63.PubMedPubMedCentral Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151–63.PubMedPubMedCentral
15.
go back to reference Devresse A, Cochat P, Godefroid N, Kanaan N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep. 2020;5(12):2136–45.CrossRefPubMedPubMedCentral Devresse A, Cochat P, Godefroid N, Kanaan N. Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep. 2020;5(12):2136–45.CrossRefPubMedPubMedCentral
16.
go back to reference Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057–64.CrossRefPubMedPubMedCentral Abdel-Kader K, Unruh ML, Weisbord SD. Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1057–64.CrossRefPubMedPubMedCentral
17.
go back to reference Devresse A, Godefroid N, Anthonissen B, Labriola L, de Magnée C, Reding R, et al. Liver transplantation in primary hyperoxaluria type 1: we have to find an alternative! Transplantation. 2021;105(4):e46–7.CrossRefPubMed Devresse A, Godefroid N, Anthonissen B, Labriola L, de Magnée C, Reding R, et al. Liver transplantation in primary hyperoxaluria type 1: we have to find an alternative! Transplantation. 2021;105(4):e46–7.CrossRefPubMed
18.
go back to reference Shee K, Ahn J, Hamouche F, Mena J, Chi T, Stoller ML. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology. 2021;156:e147–9.CrossRefPubMed Shee K, Ahn J, Hamouche F, Mena J, Chi T, Stoller ML. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology. 2021;156:e147–9.CrossRefPubMed
19.
go back to reference Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216–26.CrossRefPubMed Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216–26.CrossRefPubMed
20.
go back to reference Deschênes G, Cochat P, Magen D, van't Hoff W, Michael M, Sas D, et al. ILLUMINATE-B, a phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1) [poster]. Annual Meeting of the American Society of Nephrology. 2020. Deschênes G, Cochat P, Magen D, van't Hoff W, Michael M, Sas D, et al. ILLUMINATE-B, a phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1) [poster]. Annual Meeting of the American Society of Nephrology. 2020.
21.
go back to reference Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, et al. ILLUMINATE-C, a single-arm, phase 3 study of lumasiran in patients with primary hyperoxaluria type 1 and CKD3b-5, including those on hemodialysis [presentation]. Annual Meeting of the American Society of Nephrology; 2021. Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, et al. ILLUMINATE-C, a single-arm, phase 3 study of lumasiran in patients with primary hyperoxaluria type 1 and CKD3b-5, including those on hemodialysis [presentation]. Annual Meeting of the American Society of Nephrology; 2021.
22.
go back to reference Baum M, Langman C, Cochat P, Lieske J, Moochhala S, Hamamoto S, et al. PHYOX2: nedosiran reduced urinary oxalate excretion in patients with primary hyperoxaluria [poster]. Annual Congress of the American Society of Nephrology; 2021. Baum M, Langman C, Cochat P, Lieske J, Moochhala S, Hamamoto S, et al. PHYOX2: nedosiran reduced urinary oxalate excretion in patients with primary hyperoxaluria [poster]. Annual Congress of the American Society of Nephrology; 2021.
23.
go back to reference Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria type 1 and end-stage renal disease: a phase II study. Nephrol Dial Transplant. 2021;36(8):1464–73.CrossRefPubMed Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria type 1 and end-stage renal disease: a phase II study. Nephrol Dial Transplant. 2021;36(8):1464–73.CrossRefPubMed
27.
go back to reference Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.CrossRef Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391–409.CrossRef
28.
go back to reference Fugard AJB, Potts HWW. Supporting thinking on sample sizes for thematic analyses: a quantitative tool. Int J Soc Res Methodol. 2015;18(6):669–84.CrossRef Fugard AJB, Potts HWW. Supporting thinking on sample sizes for thematic analyses: a quantitative tool. Int J Soc Res Methodol. 2015;18(6):669–84.CrossRef
Metadata
Title
Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study
Authors
David Danese
Diana Goss
Carla Romano
Catherine Gupta
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03365-1

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine